Axxam and HeartBeat.bio Partner on Cardiovascular Drug Discovery
Research firms Axxam and HeartBeat.bio have begun a collaboration to advance human-relevant cardiovascular drug discovery and cardiac safety assessment.
Biofarmaceutical company Axxam and cardiology research firm HeartBeat.bio have entered into an agreement aimed at advancing human-relevant cardiovascular drug discovery and cardiac safety assessment.
The collaboration will leverage Axxam's expertise in drug discovery with HeartBeat.bio's unique technology, which enables in vitro modeling of human heart function. The partners aim to accelerate the identification and testing of novel drug candidates for cardiovascular diseases and improve the understanding of existing drug safety profiles.
Industry analysts suggest this partnership could significantly shorten the development cycle for new cardiovascular medications and reduce risks associated with clinical trials. The objective is to enhance patient outcomes by providing more effective and safer treatments.
The agreement was finalized without disclosing specific financial terms. Both companies anticipate this collaboration will strengthen their respective positions in the pharmaceutical research and development sector.